{"id":624,"date":"2025-09-20T03:50:04","date_gmt":"2025-09-20T03:50:04","guid":{"rendered":"https:\/\/unlistedradar.com\/blog\/?p=624"},"modified":"2025-09-20T05:25:02","modified_gmt":"2025-09-20T05:25:02","slug":"should-you-invest-in-sahajanand-medical-technologies-ipo-detailed-analysis","status":"publish","type":"post","link":"https:\/\/unlistedradar.com\/blog\/should-you-invest-in-sahajanand-medical-technologies-ipo-detailed-analysis\/","title":{"rendered":"Should You Invest in Sahajanand Medical Technologies IPO? Detailed Analysis"},"content":{"rendered":"About Sahajanand Medical Technologies<\/b><\/h2>\n
SMT began in 1999 as Sahajanand Vascular Technoventions and evolved into Sahajanand Medical Technologies Limited. Headquartered in Surat with a corporate office in Mumbai, SMT has expanded into multiple countries with subsidiaries in Ireland, Germany, Switzerland, Poland, Brazil, Spain, USA, and more.<\/span><\/p>\nThe company focuses on <\/span>vascular intervention and structural heart devices<\/b>, including:<\/span><\/p>\n\n- Drug-eluting stents (DES)<\/b><\/li>\n
- PTCA balloons<\/b><\/li>\n
- Transcatheter aortic valves<\/b><\/li>\n
- Occluders and delivery systems<\/b><\/li>\n<\/ul>\n
SMT operates R&D centres in India and Thailand and holds a large portfolio of patents and design registrations, underscoring its innovation-driven approach.<\/span><\/p>\nHistory & Land Footprint<\/h2>\n
Founded in the early 2000s, SMT expanded product lines (stents, catheters, occluders, TAVI) and international footprint through subsidiaries and strategic moves. As of FY2025, SMT reports presence in 76 countries. Manufacturing capacity includes stents (840,000 units) and catheters (960,000 units).<\/p>\n
Business Model of Sahajanand Medical<\/h2>\n
SMT combines manufacturing, R&D, clinical trials and global distribution. Revenue arises mainly from product sales supported by clinical validation and regulatory approvals for international markets.<\/p>\n
Infrastructure & Features<\/h2>\n
SMT maintains multi-country manufacturing and R&D facilities, with high capacity utilization for core VI devices and ongoing capex to scale production.<\/p>\n
Revenue Model<\/h2>\n
Primary revenue: sale of products. Geography split FY2025: India ~31.28%, Europe ~32.96%, RoW ~35.76%.<\/p>\n
Balance Sheet Strength (\u20b9 Crores)<\/h2>\n
\n\n\n| Particulars<\/th>\n | 2023<\/th>\n | 2024<\/th>\n | 2025<\/th>\n<\/tr>\n<\/thead>\n |
\n\n| Fixed Assets (PPE)<\/td>\n | 160.72<\/td>\n | 174.03<\/td>\n | 181.19<\/td>\n<\/tr>\n |
\n| Non-Current Assets<\/td>\n | 338.90<\/td>\n | 365.78<\/td>\n | 386.95<\/td>\n<\/tr>\n |
\n| Inventory<\/td>\n | 238.14<\/td>\n | 251.70<\/td>\n | 266.85<\/td>\n<\/tr>\n |
\n| Total Assets<\/td>\n | 962.30<\/td>\n | 1,028.50<\/td>\n | 1,094.90<\/td>\n<\/tr>\n |
\n| Reserves \/ Other Equity<\/td>\n | 521.40<\/td>\n | 540.85<\/td>\n | 555.97<\/td>\n<\/tr>\n |
\n| Total Equity<\/td>\n | 553.62<\/td>\n | 572.88<\/td>\n | 590.47<\/td>\n<\/tr>\n |
\n| Total Borrowings (Debt)<\/td>\n | 198.76<\/td>\n | 212.34<\/td>\n | 224.96<\/td>\n<\/tr>\n |
\n| Cash & Equivalents<\/td>\n | 84.23<\/td>\n | 92.10<\/td>\n | 100.52<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/h2>\n <\/p>\n Promoter details<\/h2>\nPromoters include Shree Hari Trust and members of the Kotadia family. Pre-offer promoter holding (Shree Hari Trust) is ~36.79%.<\/p>\n Ownership Management Team<\/h2>\nTop management includes executive leadership with industry experience; notable institutional investors pre-IPO include Samara Capital, Kotak Pre-IPO Opportunities Fund and NHPEA Sparkle Holding B.V.<\/p>\n |